Recent preclinical studies utilizing doxorubicin-induced cardiomyopathy rodent models have validated UTMD-facilitated precision delivery of multiple therapeutics - including GLP-1 (57), MaFGF (58), ANGPTL8 (59), survivin (60), and aFGF (61) - demonstrating capacity to ameliorate or reverse the established ADM cardiomyopathy. This evidence concerns the gene FGF1 and cardiomyopathy.